Mr. Hayim Raclaw reports

ALZAI HEALTH CORP. COMPLETES INITIAL PUBLIC OFFERING

Alzai Health Corp. has completed its previously announced initial public offering of 10,125,000 units of the corporation, including 125,000 offered units sold pursuant to the exercise of the agent's (as defined below) overallotment option, at a price of 40 cents per offered unit for aggregate gross proceeds of $4.05-million.

Each offered unit consisted of one common share of the corporation and one-half of one common share purchase warrant. Each warrant entitles the holder thereof to purchase, subject to acceleration and adjustment in certain circumstances, one common share at an exercise price of 60 cents until the earlier of: (i) June 9, 2028; and (ii) the date specified in any acceleration notice (as defined below) delivered in accordance with the terms of the warrant indenture dated June 9, 2026, between the corporation and Odyssey Trust Company, as warrant agent.

If, at any time, the volume-weighted average trading price of the common shares is equal to or greater than 90 cents for any 10-consecutive-trading-day period, the corporation may provide written notice to the registered holders of warrants that the expiry time of the warrants shall be accelerated to the date which is 30 days from the date of such acceleration notice, subject to approval from the TSX Venture Exchange.

The offering was completed pursuant to a long form prospectus dated April 21, 2026, filed with the Alberta Securities Commission, B.C. Securities Commission and Ontario Securities Commission.

The corporation's common shares were listed and halted on June 8, 2026, and will resume trading today on the TSX-V under the symbol ALZI. Following closing of the offering, the corporation has 64,147,682 common shares issued and outstanding, with the directors, officers and certain shareholders of the corporation holding an aggregate of 23,489,722 common shares which are subject to escrow restrictions.

Haywood Securities Inc. acted as the exclusive agent for the offering, on a best effort basis, pursuant to an agency agreement between the corporation and the agent. As consideration for the agent's services in the offering, the agent received a cash commission of $283,500, being 7 per cent of the proceeds of the offering, 708,750 non-transferable agent's warrants, being 7 per cent of the total number of units issued in the offering, and a corporate finance fee of $45,000 plus taxes (of which $24,750 was payable in cash and $22,500 was payable by the issuance of common shares at a deemed price of 40 cents per common share). Each agent's warrant is exercisable into one common share at an exercise price of 40 cents for a period of 24 months following the date of issuance.

The net proceeds from the offering will be used for research and development, sales and marketing, and general working capital, as more particularly described in the prospectus, which can be found on the corporation's profile on SEDAR+.

About Alzai Health Corp.

Alzai is a health technology corporation. Alzai's current product offering is an artificial-intelligence-driven, non-invasive Alzheimer's disease/Alzheimer's-disease-related dementia risk screening solution that uses only pre-existing patient data found in routine clinical records. Alzai's risk screening solution enables earlier identification of cognitive decline, a massive unmet need as approximately 80 per cent of Alzheimer's patients are diagnosed past the mild stages of the disease. Through risk screening, Alzai supports timely diagnosis, intervention, prevention and improved patient outcomes for efficient population-level disease management across payers, providers and clinical research.

We seek Safe Harbor.